Human medicines European public assessment report (EPAR): Temomedac, temozolomide, Glioma; Glioblastoma, Date of autho...

Human medicines European public assessment report (EPAR): Temomedac, temozolomide, Glioma;Glioblastoma, Date of authorisation: 25/01/2010, Revision: 15, Status: Authorised Human medicines European public assessment report (EPAR): Temomedac, temozolomide, Glioma;Glioblastoma, Date of authorisation: 25/01/2010, Revision: 15, Status: Authorised       Siemens Healthcare Diagnostics AIMC 22-03 - Atellica® Solution and ADVIA Centaur® Systems Siemens Healthcare Diagnostics Inc. has confirmed customer observations of falsely elevated results when using plasma specimens across the entire Analytical Measuring Range (AMR) with the Atellica IM Enhanced Estradiol (eE2) assay. Results demonstrate that plasma specimens are not meeting claims as defined in the Instructions for Use (IFU).       Neem deel aan implementatie handreiking risicomanagement LVB

Actueel zorgnieuws in jouw mailbox ontvangen?

Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.